Glanbia raises full-year profit outlook as GLP-1 users lift demand for protein products
AI Market Summary
Glanbia raised its full-year profit outlook after stronger-than-expected growth across all nutrition divisions, with Optimum Nutrition first-half sales up 25% amid increased protein consumption linked to GLP-1 weight-loss drug users. The company has implemented multiple price increases and plans another, while warning of double-digit whey cost inflation into 2026-27. The upgrade and share jump signal solid demand, partly offset by margin and volume risks from higher input costs.
Impact level
● Medium
Affected assets
NCSKS2USD/USDT-3.17%
AI Insight · NCSKS2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Nutrition supplement maker Glanbia raised its full-year profit forecast after stronger demand for its protein products, including from consumers using them alongside GLP-1 weight-loss drugs. The company said it now expects adjusted earnings per share to grow 17% to 20% at constant currencies this year. Optimum Nutrition posted 25% sales growth in the first half and Glanbia has raised prices twice since November. It also expects whey costs to rise further, according to Reuters.
